New study compares two inhaled steroids for treating wheezing in babies
NCT ID NCT07675252
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests how well and how safe fluticasone propionate nebulized suspension works in babies aged 0 to 24 months with acute wheezing. It compares fluticasone to budesonide, another commonly used inhaled steroid. About 240 babies will be randomly assigned to receive either fluticasone or budesonide twice daily for 5 to 7 days. Researchers will track breathing symptoms like wheezing, cough, and phlegm to see if fluticasone is as effective as budesonide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluticasone propionate nebulized suspension
- What this could lead to
- If fluticasone works as well or better than budesonide, it could become another safe, effective inhaled steroid option for treating wheezing in very young infants.
- What could go wrong
- This is a Phase 4 trial with 240 babies, so results may not apply to all infants. The treatment is short-term (5-7 days), and long-term effects or rare side effects may not be captured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE WHEEZING DISORDERS IN INFANTS AGED 0 TO 24 MONTHS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.